繁體版 / 簡體版
 
R&D PORTFOLIO
/ ON101

ON101

Indication
Diabetic foot ulcer (DFU)
Product Advantages
1.Anti-inflammation
2.Enhanced the skin cells migration and proliferation
3.Enhanced collagen synthesis
4.Tissue remodeling
Status
1.Taiwan new drug certificate is currently under reviewing.
2.Executing the phase III clinical trials in the China and the United States.
Product Advantages
1.Efficacy: Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation.
2.Cost advantage: Integration of new drug research and development, botanical planting, and drug product manufacturing to control costs. Exclusive share of the global DFU market.
Potential Market
Diabetic Foot Ulcer market is in value from $292.1 Million in 2015 to $873.4 Million by 2025, representing a compound annual growth rate of 11.6%.

  • The new drug ON101 for diabetic foot ulcer has reached the goal after interim analysis in phase III clinical trial in Taiwan. The complete wound healing rate is over 60% after 16 weeks treatment. The clinical efficacy of ON101 is better than the current drug Regranex. It will be the first natural source of therapeutic drugs for DFU with the greatest value in the market.
  • The patents of ON101 plant extracts, uses and process technologies have been completed with a global patent layout to protect the intellectual property and technology. The patents granted countries including the Republic of China, the United States, the European Union, Malaysia, India, Japan, China, South Korea and Russia.


体彩p5中奖新闻 黑龙江11选5前三组 北京快乐八计划 北京赛车论坛网 上海11选五5开奖结果爱彩乐 上海快3一定牛走势图 福利彩票中奖规则列表 二分时时彩是国家的吗 044期3d试机号 河南11选5奖金说明 基金配资比例两种模式